Discover the latest news from the Pulmonary Hypertension, including advocacy updates, research articles and event coverage.
Learn how pulmonary hypertension patients can stay involved in treatment decisions with insights from transplant pulmonologist Dr. Christopher King.
About PH | Diagnosis & treatment | Living with PH
The latest PHA Classroom video series, “Treating Pulmonary Hypertension,” explores treatment pathways. In the six-part series, pulmonologist Christopher King from Inova Fairfax Hospital explains how changes in body chemistry – or pathways – cause cells and organs to react abnormally. In four videos, King explains how targeted therapies work focus on specific pathways to treat PH. The other two videos focus on pulmonary vasodilator medications and patient-specific treatment plans.
Diagnosis & treatment
Affected by a rare disease? Show your stripes on Rare Disease Day, Saturday, Feb. 28, to support rare and complex conditions that affect one in 10 Americans. Together, they are 25 million strong. Whether you’ll be rocking zebra-print outfits, painting your face or baking striped cookies, join PHA on social media Saturday and share how you show your stripes, using the hashtags #PHAssociation, #ShowYourStripes and #RareDiseaseDay.
Living with PH
As the Pulmonary Hypertension Association turns 35, we have much to celebrate. In the past three decades, PHA has achieved many wins in fulfilling our mission. As we continue our work to improve and extend the lives of people affected by PH, we’re looking forward to PHA 2026 International PH Conference, Rare Disease Day on Feb. 28 and our March 9 advocacy event on Capitol Hill.
Registration opens Monday, March 2, for PHA 2026 International PH Conference and Scientific Sessions. Make sure your PHA membership is up to date to receive discounted member rates and apply for scholarships to further reduce conference costs.
Education | Events
Do you know someone who goes above and beyond for their service to the pulmonary hypertension community? Nominate them for our Outstanding Member Awards. Nominations open March 2 and close April 13. The awards recognize volunteer efforts in patient and caregiver support, advocacy, promoting quality patient care and advancing research. PHA will present the awards at PHA 2026 International PH Conference and Scientific Sessions, June 11-14 in Dallas.
Events
Ralinepag met a primary goal to delay disease progression in a Phase 3 study, United Therapeutics announced. The study met several secondary goals, including six-minute walk distance.
Read morePulmovant has completed enrollment for its Phase 2 PHocus clinical trial to evaluate a once-daily inhaled treatment for PH-ILD. Mosliciguat helps widen blood vessels and could have anti-inflammatory and anti-fibrotic properties.
Read moreGossamer Bio’s Phase 3 seralutinib trial narrowly missed its primary endpoint goal to show improved six-minute walk distance at week 24, according to its news release. An unexpectedly large improvement in walk distance in the placebo group appeared in part to influence the outcome, Gossamer says. The company noted encouraging findings in key secondary goals, including reductions in NT-proBNP, improvements in clinical status and lower risk scores. The study also showed meaningful treatment effects in patients with intermediate and high-risk PH, Gossamer explains in a document for patients (pdf).
Read more
